Public Disclosure of FDA Panel Members' Conflicts of Interest | GenomeWeb

The Scientist reports that the FDA is changing its conflict-of-interest policy. In the past, if they wanted an interest waiver, the members of the organization's 32 advisory panels and committees would simply have to tell the FDA if they had any connections with a company that had a drug or medical device under FDA review, or with one of its competitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.